Back
Science

Blood Biomarker pTau217 Shows Potential for Predicting Alzheimer's-Related Cognitive Decline Years Before Symptom Onset

Generated on: Last updated: 9 sources
View source

Blood Biomarker p-tau217 Shows Promise for Predicting Alzheimer's Risk, But Limitations Remain

A series of research studies have examined the blood biomarker p-tau217 as a potential tool for predicting the accumulation of Alzheimer's disease pathology and the onset of cognitive decline. Findings published in multiple journals, including Nature Communications, Nature Medicine, JAMA, and JAMA Network Open, and presented at the Alzheimer's Association International Conference, indicate that elevated levels of this protein in the blood may serve as an early indicator of future cognitive impairment.

However, researchers have also identified key limitations: elevated p-tau217 is not exclusive to Alzheimer's disease, and the tests are not yet recommended for routine clinical screening in asymptomatic individuals.

"The tests are not yet recommended for routine screening of asymptomatic individuals outside of research contexts."

Study Methodologies and Participant Data

The findings are based on several distinct research projects with different cohorts:

  • Mass General Brigham Study (n=317): Led by Hyun-Sik Yang, this study followed cognitively healthy participants aged 50-90 for an average of eight years. Data was collected from amyloid-beta and tau PET scans, cognitive testing, and p-tau217 blood tests. Published in Nature Communications.

  • International Cohort Study (n=~2,700): Led by Rachel Buckley (Harvard Medical School), this study tracked cognitively healthy adults with an average age of 70 for up to 10 years. Published in JAMA and presented at the Alzheimer's Association International Conference.

  • Predictive Model Study (n=603): Led by Kellen K. Petersen and Suzanne E. Schindler (Washington University School of Medicine), this study analyzed data from the Knight Alzheimer Disease Research Center and the Alzheimer's Disease Neuroimaging Initiative. Published in Nature Medicine.

  • Women's Health Initiative Study (n=2,766): Led by Aladdin H. Shadyab (UC San Diego), this study analyzed blood samples from women aged 65-79 with no initial signs of cognitive decline, tracking them for up to 25 years. Published in JAMA Network Open.

  • Systemic Amyloidosis Study (n=280): Led by researchers at DZNE and the Hertie Institute for Clinical Brain Research, this study examined data from older individuals across Germany, Italy, and the Netherlands. Published in Nature Medicine.

Key Research Findings on p-tau217

Association with Protein Accumulation and Cognitive Decline

  • Blood tests measuring p-tau217 levels closely matched PET scan results for detecting amyloid-beta and tau protein accumulations in the brain.
  • In some cases, increasing p-tau217 levels predicted changes in brain pathology before they appeared on brain scans.
  • High p-tau217 levels were associated with future Alzheimer's pathology development, while low p-tau217 levels suggested minimal risk.
  • Higher p-tau217 amounts were linked to a greater chance of cognitive decline, primarily in participants with initial signs of amyloid-beta buildup.

Timeframe for Predicting Symptom Onset

Symptom-free individuals with high p-tau217 levels had an estimated 78% chance of developing cognitive impairment within 10 years.

  • Those with moderately elevated levels faced a 45% risk over a decade.
  • A predictive model estimated symptom onset age with a margin of approximately three to four years.
  • Variations in prediction timelines were observed based on age: If p-tau217 levels increased at age 60, symptoms appeared about 20 years later; an increase at age 80 resulted in symptoms approximately 11 years later.
  • The Women's Health Initiative study identified a strong association between higher initial p-tau217 levels in the late 1990s and the subsequent development of mild cognitive impairment and dementia over up to 25 years.

Current Clinical Context and Limitations

Diagnostic Specificity

A study published in Nature Medicine found that p-tau217 is not exclusive to Alzheimer's disease. Elevated levels were observed in individuals with two forms of systemic amyloidosis (transthyretin amyloidosis and immunoglobulin light-chain amyloidosis), conditions that primarily affect the heart and kidneys. Researcher Mathias Jucker hypothesized that cells may release pTau as a stress response to amyloid deposits in various organs.

Clinical Recommendations

  • Researchers, including lead author Schindler, cautioned against individuals taking these tests independently until further studies are concluded.
  • Maria Carrillo, chief science officer at the Alzheimer's Association, stated that targeting the silent stage before memory issues arise is where future treatments could have the greatest impact.
  • The tests are currently used to confirm Alzheimer's diagnosis in patients already experiencing cognitive impairment but are not recommended for routine screening of asymptomatic individuals outside of research contexts.

Factors Influencing Biomarker Levels and Risk

Researchers noted multiple factors that influence p-tau217 levels and dementia risk:

  • Age: Influences the speed of symptom development after p-tau217 levels rise, with older adults tending to develop symptoms sooner. Women over 70 with higher p-tau217 levels showed poorer cognitive outcomes compared to those under 70.
  • Genetics: The biomarker was a stronger predictor of dementia in women with the APOE ε4 gene.
  • Kidney Function: Can influence biomarker levels.
  • Race: Racial background can influence biomarker levels and dementia risk.
  • Hormone Therapy: The biomarker was a stronger predictor in women who received estrogen and progestin therapy.
  • Specific Demographics: The Women's Health Initiative study focused exclusively on older women, and findings might not apply to men or younger populations.

"These tests are not yet ready for independent use by individuals. Further studies are needed."

Future Research Directions

Researchers across all studies outlined several next steps:

  • Gathering more data to improve prediction algorithm accuracy.
  • Conducting longer studies in larger and more diverse populations.
  • Investigating the interaction of factors such as genetics, hormone therapy, and age-related medical conditions with plasma p-tau217.
  • Combining p-tau217 with other blood-based biomarkers to refine predictions.
  • Validating the tests for potential use in recruiting participants for clinical trials of preventive treatments.